Business
CSL profits boom 45pc as flu business soars – The Australian Financial Review
The blood products giant notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half.
Sales of CSLs Hizentra product grew strongly, up 19 per cent, reflecting the benefits of home administration and the continued strong uptake for the treatment of the debilitating neurological disorder CIDP (chronic inflammatory demyelinating polyneuropathy).
The company declared a dividend of $US1.04 per share, up 9 per cent.
Guidance maintained
Despite the strong growth in the first half, the company maintained its full-year guidance of net profit of $US2.17 billion to $US2.265 billion at constant…
-
General16 hours agoClean-up underway after stormy weather hits, 400 calls for help in Sydney
-
Noosa News18 hours agoFeral pigs devour 99 out of every 100 lambs on this Central West NSW farm
-
General7 hours agoMelbourne Cup five quick hits: Melham magic, Blake Shinn falls, and concern over blood from Half Yours’s mouth
-
General5 hours agoOsborne Park Football Club suspended for two years after Stephen Hawking costume controversy